Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

130.34 +1.23 (+0.95%)
Streaming Delayed Price Updated: 9:37 AM EST, Jan 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
70 71 Next >
News headline image
Assessing Gilead Sciences: Insights From 15 Financial Analysts ↗
 
Via Benzinga
News headline image
Gilead Cancer Drug Combined With Merck's Drug Effective In Difficult To Treat Type Of Breast Cancer ↗
Gilead's Trodelvy and Merck's Keytruda improved progression-free survival in PD-L1+ metastatic TNBC in a Phase 3 trial with no new safety concerns. 
Via Benzinga
News headline image
Gilead Announces Positive Results From Trodelvy-Keytruda Combo Study For Breast Cancer: But Retail’s Unmoved ↗
Triple-negative breast cancer accounts for approximately 15% of all breast cancers and has a higher chance of recurrence. 
Via Stocktwits
News headline image
Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Why Quality Investors May Find GILEAD SCIENCES INC (NASDAQ:GILD) Attractive. ↗
A fundamental analysis of (NASDAQ:GILD) shows GILEAD SCIENCES INC (NASDAQ:GILD) may be suited for quality investing, we'll explore why in this article. 
Via Chartmill
News headline image
2 High-Yielding ETFs Retirees Can Safely Build Their Portfolios Around ↗
Via The Motley Fool
Topics ETFs Economy World Trade
News headline image
Time 100 Most Influential People Includes Elon Musk, Mark Zuckerberg, Alex Karp And More Public Company CEOs ↗
The Time 100 list of the most influential people in the world includes Elon Musk, Mark Zuckerberg and several other CEOs of publicly traded companies. 
Via Benzinga
News headline image
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction ↗
Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating... 
Via Benzinga
Topics Government
News headline image
3 Reasons GILD is Risky and 1 Stock to Buy Instead
In a sliding market, Gilead Sciences has defied the odds, trading up to $106.42 per share. Its 24% gain since October 2024 has outpaced the S&P 500’s 6.9% drop. This was partly due to its solid... 
Via StockStory
Topics Stocks
News headline image
Is Iovance Biotherapeutics a Millionaire-Maker? ↗
Via The Motley Fool
News headline image
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies ↗
Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs. 
Via Benzinga
Topics Government World Trade
News headline image
Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025
From Gilead Sciences, Inc.
Via Business Wire
News headline image
S&P, Dow Jones Pharma Names Rattled — Again — On Trump's Tariffs Whiplash ↗
Here's why the 90-day tariffs delay doesn't help pharmaceutical companies. 
Via Investor's Business Daily
Topics Government Stocks World Trade
News headline image
Rule Breaker Investing: Essays From Yesterday, Vol. 7 ↗
Via The Motley Fool
News headline image
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline ↗
Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs. 
Via Benzinga
Topics Government Supply Chain World Trade
News headline image
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. ↗
The US market session of Wednesday has yet to be opened, let's have a look at the top S&P500 gainers and losers in the pre-market session today. 
Via Chartmill
News headline image
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports ↗
Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports. 
Via Investor's Business Daily
Topics Government Stocks World Trade
News headline image
2 Top Dividend Stocks That Could Set You Up for Life ↗
Via The Motley Fool
Topics Government Initial Public Offering Intellectual Property
News headline image
Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks ↗
Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies. 
Via Benzinga
Topics Government World Trade
News headline image
Amazon, Alphabet, KLA And A Health Care Stock On CNBC's 'Final Trades' ↗
 
Via Benzinga
News headline image
Intel's New CEO Outlines Recovery Strategy. Wall Street Remain Cautious. ↗
Intel's new CEO, Lip-Bu Tan, offered his strategy for turning around the troubled chipmaker in a speech late Monday. But Intel stock fell. 
Via Investor's Business Daily
News headline image
2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating
JPMorgan's upgrade on Gilead sparks bullish sentiment for the healthcare sector—here's why stocks like Pfizer and Hims & Hers are promising opportunities. 
Via MarketBeat
News headline image
1 Healthcare Stock to Target This Week and 2 to Turn Down
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the... 
Via StockStory
Topics Stocks
News headline image
If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
What Analysts Are Saying About Gilead Sciences Stock ↗
 
Via Benzinga
News headline image
A Closer Look at Gilead Sciences's Options Market Dynamics ↗
 
Via Benzinga
News headline image
Merck's Biggest Moneymaker Could Get Even Bigger. But Will It Help Downtrodden Shares? ↗
The FDA is due to make an approval decision in mid-September for a key product from the top pharma company. 
Via Investor's Business Daily
News headline image
No Quick Fix For This Market ↗
Despite the pullback, we have found numerous opportunities which we discuss in this video using technical analysis. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed ↗
UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness. 
Via Benzinga
News headline image
Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its... 
Via StockStory
Topics Artificial Intelligence
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
70 71 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.